RSV causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon.

Data on the protection conferred by COVID-19 vaccination and previous SARS-CoV-2 infection against omicron (B.1.1.529) infection in young children are scarce.

In order to better define the need for influenza vaccination in people with diabetes (DM), we collected all available evidence on the effect of DM as a risk factor for complications of both seasonal and pandemic influenza.

Ahead of the UN High-level Meeting on Pandemic Prevention, Preparedness, and Response, taking place in September, ESWI has joined the Pandemic Action Network, alongside more than 90 partners, in signing a political declaration calling leaders for action.

The sequelae of SARS-CoV-2 infection can involve multiple organ systems and are often grouped together as “long Covid” or PASC (postacute sequelae of SARS-CoV-2)

The European Public Health Alliance's manifesto presents five key priorities, aiming at strengthening public health and securing the EU’s resilience by working on pandemic preparedness and response.

What do we know about long-Covid? In this captivating episode we listen to the personal and powerful account of how the lingering effects of Sars-CoV-2 has wreaked havoc in an otherwise healthy person.

Why should older adults be particularly careful of acute respiratory viruses? What are risk factors for adverse outcomes? Why is RSV typically under-diagnosed in adults compared with flu and what are some of the long-term impacts?

The shocking numbers of babies and children who die, or who are in need of care, coupled with the rising number of undiagnosed older adults puts a significant burden from RSV on health systems.

The EC has authorised Arexvy, the first vaccine to protect adults aged 60 years and older, against RSV. This decision marks an important step and has been particularly awaited in light of the increased RSV infections in the EU last winter.

In 2022, almost 76 million people in the EU aged 15 to 74 were employed in science and technology (+2.5% compared with 2021). Of the 76 million people employed in science and technology, 52% were women (no change compared with 2021).

Science|Business organised a roundtable discussion with international experts -representing industry, academia, public health bodies, think tanks, government officials and research organisations- to discuss how to prepare for future pandemics.